You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNialamide
Accession NumberDB04820
TypeSmall Molecule
GroupsWithdrawn
DescriptionWithdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Structure
Thumb
Synonyms
1-(2-(Benzylcarbamoyl)ethyl)-2-isonicotinoylhydrazine
1-[2-(Benzylcarbamoyl)ethyl]-2-isonicotinoylhydrazine
2-(2-(Benzylcarbamoyl)ethyl)hydrazide isonicotinic acid
2-(2-(Benzylcarbamoyl)ethyl)hydrazide, isonicotinic acid
2-(2-(Benzylcarbamyl)ethyl)hydrazide isonicotinic acid
2-[2-(Benzylcarbamoyl)ethyl]hydrazide isonicotinic acid
BEIH
Isonicitinic acid 2-[(2-benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid 2-((2-benzylcarbamoyl)ethyl)hydrazide
Isonicotinic acid, {2-[2-(benzylcarbamoyl)ethyl]hydrazide}
Isonicotinic acid, {2-[2-(benzylcarbamoylethyl]hydrazide}
Isonicotinic acid, 2-(2-(benzylcarbamoyl)ethyl)hydrazide
Isonicotinic acid, 2-[2- (benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid, 2-[2-(benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid, 2-[2-(benzylcarbamoylethyl]hydrazide
N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
N-Benzyl-3-(2-isonicotinoylhydrazino)propanamide
N-benzyl-beta-(isonicotinoylhydrazine)propionamide
N-benzyl-beta-(isonicotinylhydrazino)propionamide
N-isonicotinoyl-n'(beta-n-benzylcarboxamidoethyl)hydrazine
N-isonicotinyl hydrazide
Nialamida
Nialamidum
Pyridine-4-carboxylic 2-[2-(benzylcarbamoyl)ethyl]hydrazide
External Identifiers
  • Lopac-N-1392
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DelmoneurinaNot Available
EsprilNot Available
IsalizinaNot Available
MygalNot Available
NF-xIIINot Available
NialamidNot Available
NiamidNot Available
NiamidalNot Available
NiamideNot Available
NiaquitilNot Available
NiazinNot Available
NovazidNot Available
NuredalNot Available
NyazinNot Available
NyezinNot Available
PsicodistenNot Available
SurgexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIT2Q0RYM725
CAS number51-12-7
WeightAverage: 298.3397
Monoisotopic: 298.14297584
Chemical FormulaC16H18N4O2
InChI KeyNOIIUHRQUVNIDD-UHFFFAOYSA-N
InChI
InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)
IUPAC Name
N-benzyl-3-(pyridin-4-ylformohydrazido)propanamide
SMILES
O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNialamide was one of the first MAOI (monoamine oxidase inhibitor) antidepressants. It is chemically related to iproniazide, another MAOI derived from isonicotinic acid. //
TargetKindPharmacological actionActionsOrganismUniProt ID
Amine oxidase [flavin-containing] BProteinunknownNot AvailableHumanP27338 details
Amine oxidase [flavin-containing] AProteinunknownNot AvailableHumanP21397 details
Catechol O-methyltransferaseProteinunknownNot AvailableHumanP21964 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineNialamide may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineNialamide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineNialamide may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineNialamide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINENialamide may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcarboseNialamide may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololNialamide may increase the hypotensive activities of Acebutolol.Approved
AlbiglutideNialamide may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Nialamide.Approved, Illicit
AliskirenNialamide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nialamide.Approved, Investigational
AlogliptinNialamide may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololNialamide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Nialamide.Approved
AmbrisentanNialamide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineNialamide may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineNialamide may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineNialamide may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Nialamide is combined with Amoxapine.Approved
AmphetamineNialamide may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Nialamide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nialamide is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Nialamide is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Arformoterol.Approved, Investigational
AtenololNialamide may increase the hypotensive activities of Atenolol.Approved
AtomoxetineNialamide may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineNialamide may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Bambuterol.Approved
BenazeprilNialamide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideNialamide may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinNialamide may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineNialamide may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilNialamide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Nialamide.Approved
BetaxololNialamide may increase the hypotensive activities of Betaxolol.Approved
BethanidineNialamide may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Nialamide is combined with Bezafibrate.Approved
BimatoprostNialamide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololNialamide may increase the hypotensive activities of Bisoprolol.Approved
BosentanNialamide may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumNialamide may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Nialamide is combined with Brimonidine.Approved
BrimonidineNialamide may increase the hypotensive activities of Brimonidine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Nialamide.Approved, Investigational
BupranololNialamide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nialamide.Approved, Illicit, Investigational, Vet Approved
BupropionNialamide may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nialamide.Approved, Investigational
CabergolineThe metabolism of Cabergoline can be decreased when combined with Nialamide.Approved
CanagliflozinNialamide may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanNialamide may increase the hypotensive activities of Candesartan.Approved
CandoxatrilNialamide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilNialamide may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nialamide.Approved, Investigational
CaroxazoneNialamide may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololNialamide may increase the hypotensive activities of Carteolol.Approved
CarvedilolNialamide may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololNialamide may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideNialamide may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineNialamide may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideNialamide may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneNialamide may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilNialamide may increase the hypotensive activities of Cilazapril.Approved
CirazolineNialamide may increase the hypertensive activities of Cirazoline.Experimental
CitalopramNialamide may increase the serotonergic activities of Citalopram.Approved
ClemastineNialamide may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Clenbuterol.Approved, Vet Approved
ClomipramineNialamide may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineNialamide may increase the hypotensive activities of Clonidine.Approved
CryptenamineNialamide may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Nialamide.Approved
CyclothiazideNialamide may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineNialamide may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinNialamide may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineNialamide may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinNialamide may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineNialamide may increase the hypotensive activities of Deserpidine.Approved
DesipramineNialamide may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineNialamide may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateNialamide may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineNialamide may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanNialamide may increase the serotonergic activities of Dextromethorphan.Approved
DiazoxideNialamide may increase the hypotensive activities of Diazoxide.Approved
DiethylpropionNialamide may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineNialamide may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Nialamide.Approved
DiltiazemNialamide may increase the hypotensive activities of Diltiazem.Approved
DipivefrinThe risk or severity of adverse effects can be increased when Nialamide is combined with Dipivefrin.Approved
DisopyramideNialamide may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Nialamide is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideNialamide may increase the hypotensive activities of Dorzolamide.Approved
DosulepinNialamide may increase the serotonergic activities of Dosulepin.Approved
DoxapramNialamide may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinNialamide may increase the hypotensive activities of Doxazosin.Approved
DoxepinNialamide may increase the serotonergic activities of Doxepin.Approved
DoxylamineNialamide may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Nialamide is combined with Droxidopa.Approved, Investigational
DulaglutideNialamide may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineNialamide may increase the serotonergic activities of Duloxetine.Approved
EfonidipineNialamide may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Nialamide.Approved, Investigational
EmpagliflozinNialamide may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilNialamide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatNialamide may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Nialamide.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Nialamide is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineNialamide may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolNialamide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanNialamide may increase the hypotensive activities of Eprosartan.Approved
ErgotamineNialamide may increase the hypertensive activities of Ergotamine.Approved
EscitalopramNialamide may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineNialamide may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Nialamide.Approved
EtoperidoneNialamide may increase the serotonergic activities of Etoperidone.Approved
ExenatideNialamide may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineNialamide may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Nialamide is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamNialamide may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Nialamide.Approved, Illicit, Investigational, Vet Approved
FluoxetineNialamide may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineNialamide may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Formoterol.Approved, Investigational
FosinoprilNialamide may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Nialamide.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Nialamide.Approved, Vet Approved
GliclazideNialamide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideNialamide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideNialamide may increase the hypoglycemic activities of Glipizide.Approved
GlyburideNialamide may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzNialamide may increase the hypotensive activities of Guanabenz.Approved
GuanadrelNialamide may increase the hypotensive activities of Guanadrel.Approved
GuanethidineNialamide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineNialamide may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumNialamide may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineNialamide may increase the hypertensive activities of Hydracarbazine.Approved
HydralazineNialamide may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideNialamide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideNialamide may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideNialamide may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
ImidaprilNialamide may increase the hypotensive activities of Imidapril.Investigational
ImipramineNialamide may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Indacaterol.Approved
IndalpineNialamide may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideNialamide may increase the hypotensive activities of Indapamide.Approved
IndenololNialamide may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminNialamide may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartNialamide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirNialamide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineNialamide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineNialamide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanNialamide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproNialamide may increase the hypoglycemic activities of Insulin Lispro.Approved
IproclozideNialamide may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Nialamide.Withdrawn
IrbesartanNialamide may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Nialamide.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Nialamide is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Nialamide is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Nialamide is combined with Isoprenaline.Approved
IsradipineNialamide may increase the hypotensive activities of Isradipine.Approved
KetanserinNialamide may increase the hypotensive activities of Ketanserin.Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Nialamide.Approved, Nutraceutical
LabetalolNialamide may increase the hypotensive activities of Labetalol.Approved
LacidipineNialamide may increase the hypotensive activities of Lacidipine.Approved
LanreotideNialamide may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostNialamide may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineNialamide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Nialamide.Approved
LevomilnacipranNialamide may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinNialamide may increase the hypertensive activities of Levonordefrin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Nialamide is combined with Linezolid.Approved, Investigational
LiraglutideNialamide may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineNialamide may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilNialamide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Nialamide.Approved
LithiumThe risk or severity of adverse effects can be increased when Nialamide is combined with Lithium.Approved
LofexidineNialamide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanNialamide may increase the hypotensive activities of Losartan.Approved
Lu AA21004The metabolism of Lu AA21004 can be decreased when combined with Nialamide.Investigational
MacitentanNialamide may increase the hypotensive activities of Macitentan.Approved
ManidipineNialamide may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nialamide.Approved
MebanazineNialamide may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineNialamide may increase the hypotensive activities of Mecamylamine.Approved
MecaserminNialamide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneNialamide may increase the hypertensive activities of Mephedrone.Investigational
MephentermineNialamide may increase the hypertensive activities of Mephentermine.Approved
MequitazineNialamide may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolNialamide may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminNialamide may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Methadone.Approved
MethamphetamineNialamide may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoxamineNialamide may increase the hypertensive activities of Methoxamine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nialamide is combined with Methyldopa.Approved
Methylene blueNialamide may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateNialamide may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololNialamide may increase the hypotensive activities of Metipranolol.Approved
MetolazoneNialamide may increase the hypotensive activities of Metolazone.Approved
MetoprololNialamide may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineNialamide may increase the hypotensive activities of Metyrosine.Approved
MianserinNialamide may increase the neurotoxic activities of Mianserin.Approved
MibefradilNialamide may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineNialamide may increase the hypertensive activities of Midodrine.Approved
MifepristoneNialamide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolNialamide may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranNialamide may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Nialamide.Approved
MinoxidilNialamide may increase the hypotensive activities of Minoxidil.Approved
MirtazapineNialamide may increase the central neurotoxic activities of Mirtazapine.Approved
MMDANialamide may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Nialamide is combined with Moclobemide.Approved
MoexiprilNialamide may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Nialamide is combined with Morphine.Approved, Investigational
MoxonidineNialamide may increase the hypotensive activities of Moxonidine.Approved
NadololNialamide may increase the hypotensive activities of Nadolol.Approved
NaftopidilNialamide may increase the hypotensive activities of Naftopidil.Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Nialamide.Approved, Investigational
NateglinideNialamide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololNialamide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNialamide may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NicardipineNialamide may increase the hypotensive activities of Nicardipine.Approved
NicorandilNialamide may increase the hypotensive activities of Nicorandil.Approved
NiguldipineNialamide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNialamide may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNialamide may increase the hypotensive activities of Nimodipine.Approved
NisoldipineNialamide may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineNialamide may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideNialamide may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineNialamide may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineNialamide may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinNialamide may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotideNialamide may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Nialamide is combined with Olanzapine.Approved, Investigational
OlmesartanNialamide may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Olodaterol.Approved
OmapatrilatNialamide may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolNialamide may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Nialamide is combined with Orciprenaline.Approved
OxprenololNialamide may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nialamide.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Nialamide.Approved
ParoxetineNialamide may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideNialamide may increase the hypoglycemic activities of Pasireotide.Approved
PenbutololNialamide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineNialamide may increase the hypoglycemic activities of Pentamidine.Approved
PentoliniumNialamide may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Nialamide.Approved, Vet Approved, Withdrawn
PerindoprilNialamide may increase the hypotensive activities of Perindopril.Approved
PethidineNialamide may increase the serotonergic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Nialamide.Approved
PheniprazineNialamide may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoxybenzamineNialamide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineNialamide may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineNialamide may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineNialamide may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineNialamide may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Nialamide is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Nialamide.Approved, Illicit
PinacidilNialamide may increase the hypotensive activities of Pinacidil.Withdrawn
PindololNialamide may increase the hypotensive activities of Pindolol.Approved
PioglitazoneNialamide may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Pirbuterol.Approved
PirlindoleNialamide may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineNialamide may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenNialamide may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideNialamide may increase the hypotensive activities of Polythiazide.Approved
PramlintideNialamide may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinNialamide may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Procaterol.Approved
PropranololNialamide may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineNialamide may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Nialamide.Investigational
PseudoephedrineNialamide may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilNialamide may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineNialamide may increase the hypoglycemic activities of Quinine.Approved
RamiprilNialamide may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Nialamide.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Nialamide.Approved
RemikirenNialamide may increase the hypotensive activities of Remikiren.Approved
RepaglinideNialamide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineNialamide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Nialamide is combined with Reserpine.Approved
RilmenidineNialamide may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatNialamide may increase the hypotensive activities of Riociguat.Approved
RitobegronNialamide may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Nialamide is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Nialamide.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Nialamide.Approved, Investigational
RosiglitazoneNialamide may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineNialamide may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Nialamide is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Salmeterol.Approved
SaprisartanNialamide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinNialamide may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Nialamide.Approved, Investigational, Vet Approved
SelexipagNialamide may increase the hypotensive activities of Selexipag.Approved
SertralineNialamide may increase the serotonergic activities of Sertraline.Approved
SitagliptinNialamide may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanNialamide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilNialamide may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Nialamide.Approved, Investigational
SulfadiazineNialamide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleNialamide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleNialamide may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Nialamide.Approved, Investigational
SunitinibNialamide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Nialamide.Approved
TelmisartanNialamide may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilNialamide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Nialamide is combined with Terbutaline.Approved
TerlipressinNialamide may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Nialamide.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nialamide.Approved
TetryzolineNialamide may increase the hypertensive activities of Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Nialamide.Approved
TiboloneNialamide may increase the hypotensive activities of Tibolone.Approved
TicrynafenNialamide may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololNialamide may increase the hypotensive activities of Timolol.Approved
TolazamideNialamide may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineNialamide may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideNialamide may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nialamide.Approved, Withdrawn
ToloxatoneNialamide may increase the hypertensive activities of Toloxatone.Approved
TorasemideNialamide may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Nialamide.Approved, Investigational
TrandolaprilNialamide may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Nialamide.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Nialamide.Approved
TravoprostNialamide may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Trazodone.Approved, Investigational
TreprostinilNialamide may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideNialamide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinNialamide may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanNialamide may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineNialamide may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneNialamide may increase the hypotensive activities of Unoprostone.Approved
ValsartanNialamide may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineNialamide may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Nialamide.Approved
VinpocetineNialamide may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nialamide.Approved
XylometazolineNialamide may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineNialamide may increase the serotonergic activities of Zimelidine.Withdrawn
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Nialamide.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Benady DR, Clein LJ, Pare CM: Intramuscular nialamide in intractable depression. Dis Nerv Syst. 1965 Dec;26(12):792-4. [PubMed:5321917 ]
  2. OULES J, CAZABON: [TREATMENT OF DEPRESSIVE STATES WITH INTRAVENOUS NIAMIDE]. Toulouse Med. 1964 Dec;65:1298-302. [PubMed:14272189 ]
  3. VAISBERG M, McGAHEE CL, RADINGER N, SAUNDERS JC: Nialamide for the treatment of anergy and depression. Dis Nerv Syst. 1959 Aug;20(Suppl):22-5. [PubMed:13840714 ]
External Links
ATC CodesN06AF02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9828
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5586
P-glycoprotein substrateNon-substrate0.589
P-glycoprotein inhibitor IInhibitor0.5514
P-glycoprotein inhibitor IINon-inhibitor0.8207
Renal organic cation transporterNon-inhibitor0.6666
CYP450 2C9 substrateNon-substrate0.8668
CYP450 2D6 substrateNon-substrate0.7826
CYP450 3A4 substrateNon-substrate0.6434
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8818
CYP450 2D6 inhibitorInhibitor0.816
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7334
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7368
BiodegradationNot ready biodegradable0.9791
Rat acute toxicity2.2756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7944
hERG inhibition (predictor II)Inhibitor0.5599
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151.6 °CPhysProp
logP0.87HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0873 mg/mLALOGPS
logP0.65ALOGPS
logP0.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.65ChemAxon
pKa (Strongest Basic)3.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.12 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity93.91 m3·mol-1ChemAxon
Polarizability32.07 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.64 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentBeta amino acids and derivatives
Alternative Parents
Substituents
  • Beta amino acid or derivatives
  • Pyridine carboxylic acid or derivatives
  • Phenylmethylamine
  • Benzylamine
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Hovevey-Sion D, Kopin IJ, Stull RW, Goldstein DS: Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology. 1989 Aug;28(8):791-7. [PubMed:2506486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Hovevey-Sion D, Kopin IJ, Stull RW, Goldstein DS: Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology. 1989 Aug;28(8):791-7. [PubMed:2506486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Parvez S, Parvez SH, Youdim MB: Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy. Br J Pharmacol. 1975 Feb;53(2):241-6. [PubMed:1170911 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:20 / Updated on August 17, 2016 12:24